Tiziano Bandiera studied at the University of Pavia (Italy) where he earned his Ph.D. degree in Chemistry in 1987.
He moved then to the pharmaceutical industry and worked at Farmitalia-Carlo Erba, Pharmacia Corp., and Nerviano Medical Sciences. His career in the industry started as researcher in the Central Nervous System therapeutic area, where his main activity was targeted at the discovery of potential new treatments for Alzheimer’s disease. In 1998, he moved to the Oncology field, and worked as project leader of preclinical discovery projects focusing on the search for antagonists of the αvß3 integrin, tyrosine kinase inhibitors, and inhibitors of arginine methyltransferases.
In 2008, he joined the Istituto Italiano di Tecnologia to set up the Medicinal Chemistry group of the Drug Discovery and Development (D3) department. He is Senior Researcher and, since 2013, Principal Investigator of the PharmaChemistry Line of the Technologies for Life Science (LifeTech) Research Domain. His research activities are mainly focused on the identification of potential new drugs for the treatment of cystic fibrosis and inflammatory diseases.
Dr. Bandiera has published more than 70 papers in peer-reviewed journals and is an inventor in 42 patents and patent applications. He is member of the Board of the Medicinal Chemistry Division of the Italian Chemical Society.